CMS needs to strengthen its internal controls to ensure Part B drug payment accuracy, OIG finds
The Office of the Inspector General within HHS today called on the Centers for Medicare & Medicaid Services (and CMS agreed) to improve the accuracy of its Medicare Part B drug payment data.
The recommendation comes as drug pricing transparency has been a sore spot across the US, and as OIG identified major gaps in how CMS tracks such data, noting that invalid or missing average sales price data meant that CMS “could not calculate an ASP-based payment amount for 8 percent of drug codes at least once between 2016 and 2020.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
